Zobrazeno 1 - 10
of 43
pro vyhledávání: '"and Dennis J. Underwood"'
Autor:
Kimberly A. Chianese-Bullock, Craig L. Slingluff, Susan C. Modesitt, Victor H. Engelhard, Kara L. Cummings, Rachel M Lacy, Paisley T. Myers, Erin D. Jeffery, Amanda M. Lulu, Dennis J. Underwood
Publikováno v:
Cancer Immunol Res
Elevated immunity to cancer-expressed antigens can be detected in people with no history of cancer and may contribute to cancer prevention. We have previously reported that MHC-restricted phosphopeptides are cancer-expressed antigens and targets of i
Publikováno v:
Expert opinion on biological therapy. 22(8)
Antibody therapies have made huge strides in providing safe and efficacious drugs for autoimmune, cancer, and infectious diseases. These bispecific antibodies can be assembled from the basic building blocks of IgGs, resulting in dozens of formats.It
Autor:
Nicholas S. Wilson, Dhan Chand, Min Lim, Dennis J. Underwood, Anthony W. Tolcher, Irina M. Shapiro, Anna Wijatyk, Mark Findeis, David Savitsky, Richard D. Carvajal, Jennifer Buell, Vignesh Venkatraman, Lernik Ohanjanian, James Strauss, Marc Van Dijk, Marilyn Marques, Claire Galand, Olga Ignatovich, Benjamin Morin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background CD137 (4-1BB) represents a costimulatory pathway that promotes T, NK, and dendritic cell effector functions favorable for antitumor immunity. The extracellular domain of CD137, comprised of four cysteine-rich domains (CRD-I, CRD-II, CRD-II
Autor:
Bishnu P. Joshi, Katharina Winkelbach, Armen Karapetyan, John C. Castle, Dennis J. Underwood, R.B. Stein, Marc Van Dijk, Volker Seibert, Chawaree Chaipan, Sandra Wimberger, Jun Seop Jeong
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 10 (2019)
Frontiers in Immunology, Vol 10 (2019)
Adoptive T cell therapy using patient T cells redirected to recognize tumor-specific antigens by expressing genetically engineered high-affinity T-cell receptors (TCRs) has therapeutic potential for melanoma and other solid tumors. Clinical trials im
Autor:
Dhan Chand, Benjamin Morin, Jennifer Buell, Ekaterina Breous-Nystrom, Jeremy D. Waight, Jedd D. Wolchok, Taha Merghoub, Elise Drouin, Nicholas S. Wilson, Christopher Clarke, Marc Van Dijk, Christopher D. Dupont, Cornelia Anne Mundt, David Savitsky, Andrea Schuster, Mark Findeis, Dennis J. Underwood, Benjamin Duckless, Mariana Manrique, Rebecca Ward, Gerd Ritter, Randi Gombos, Ana M. Martín González, Robert Stein, Jean Marie Cuillerot, Hao Tang, David Schaer
Publikováno v:
PLoS ONE, Vol 13, Iss 4, p e0191926 (2018)
PLoS ONE
PLoS ONE
CTLA-4 and CD28 exemplify a co-inhibitory and co-stimulatory signaling axis that dynamically sculpts the interaction of antigen-specific T cells with antigen-presenting cells. Anti-CTLA-4 antibodies enhance tumor-specific immunity through a variety o
Autor:
Randi Gombos, Matthew Costa, Claire Galand, Nicholas S. Wilson, Olga Ignatovich, Cailin E. Joyce, Dennis J. Underwood, David Savitsky, Benjamin Morin, Vignesh Venkatraman, Cornelia Anne Mundt, Min Lim, Christina Riordan, R.B. Stein, Rebecca M. Ward, Yanping Xiao, Dhan Chand, Mark Findeis, Marc van Dijk
Publikováno v:
Journal of Clinical Oncology. 37:e14005-e14005
e14005 Background: Agonist antibodies targeting CD137 are potent inducers of tumor-reactive T cell proliferation, cytokine production, and cytotoxicity, and have been explored clinically for their ability to enhance immune cell-mediated destruction o
Autor:
Joseph Connolly, Robert Stein, Reid Huber, Nicholas S. Wilson, Ekaterina Breous-Nystrom, Mark Findeis, Priyadarshini Iyer, Marc van Dijk, Peggy Scherle, Dennis J. Underwood, Christina Riordan, Horacio Nastri, Gregory Hollis, Michele Sanicola-Nadel, Jeremy D. Waight
Publikováno v:
Cancer Research. 78:3825-3825
Unprecedented rates of durable clinical responses have been observed for antibody-based therapeutics targeting immune checkpoint proteins such as cytotoxic T lymphocyte antigen-4 (CTLA-4) or programmed death receptor-1 (PD-1). Nonetheless, a signific
Autor:
Shawn Jennings, Horacio Nastri, Peggy Scherle, Reid Huber, Christina Riordan, Robert Stein, Rebecca M. Ward, Joseph Connolly, Nicholas S. Wilson, Marc van Dijk, David Savitsky, Dennis J. Underwood, Gregory Hollis, Michele Sanicola, Cornelia Anne Mundt, Mark Findeis
Publikováno v:
Cancer Research. 78:3819-3819
Lymphocyte activation gene 3 (LAG-3) is a cell surface receptor that negatively regulates antigen-specific T cell responses. LAG-3 expression is generally restricted to populations of recently activated and chronically stimulated exhausted T cells, a
Autor:
Nicholas S. Wilson, Dennis J. Underwood, Kimberli J. Brill, Jeremy D. Waight, Lukasz Swiech, Gregory Hollis, Kevin N. Heller, Shiwen Lin, Peggy Scherle, David Schaer, Ana M. Martín González, Robert Stein, Olivier Leger, Taha Merghoub, Roberta Zappasodi, Jennifer Buell, Ekaterina Breous, Reid Huber, Gerd Ritter, Volker Seibert, Yuqi Liu, Mariana Manrique, Marc van Dijk, Thomas Horn
Publikováno v:
Cancer Research. 77:3643-3643
Glucocorticoid-induced TNFR family related protein (GITR, CD357 or TNFRSF18) is a member of the tumor necrosis factor receptor superfamily (TNFRSF). Like other T cell co-stimulatory TNFR family members, GITR utilizes multiple oligomerization states t
Autor:
Daniel L. Levey, Mohamed Uduman, Antoine Tanne, Paisley T. Myers, Benjamin Morin, Jeffrey Raizer, Dennis J. Underwood, Shiwen Lin, Robert Stein, Mithun Khattar, Donald F. Hunt, Bishnu P. Joshi, Victor H. Engelhard, John C. Castle, Sandra Craig, Nicholas S. Wilson, Armen Karapetyan, Elise Drouin, Mark Findeis, Jennifer Buell, Erin D. Jeffery, John M. Goldberg, Amy Yang, Mark Cobbold
Publikováno v:
Cancer Research. 77:4609-4609
Most cancer cells carry mutations unique to the patient’s individual tumor and shared biochemical signatures that are not present in healthy cells. Agenus has three vaccine platforms designed to treat cancers based on the unique needs of a given pa